07:00 , May 23, 2005 |  BioCentury  |  Finance

U.S. investment in Europe

U.S. investment in Europe Company Name Country Raised Investors Arpida Switzerland $67.4 Swissfirst; Temasek Capital; Carnegie Asset Management; CDIB BioScience Ventures; CITA; MVI Medical Venture Investments; Schroder Ventures Life Sciences; Alta Berkeley Associates; Aventic; BioMedinvest;...
07:00 , Apr 18, 2005 |  BioCentury  |  Finance

Ebb & Flow

As the sign says, "objects in the rear view mirror are closer than they appear." On the heels of last week's positive Phase III data for Avastin as first-line therapy for metastatic breast cancer, and...
07:00 , May 17, 2004 |  BioCentury  |  Finance

Ebb & Flow

With 21 U.S. IPOs already floated in the States since last October, European investors have been waiting for the European biotech window to crack open. One could argue talk is still cheap, but many now...
07:00 , May 11, 2004 |  BC Extra  |  Top Story

Arpida raises CHF 51.3M

Infectious disease company Arpida (Basel, Switzerland) raised CHF 51.3 million ($39.4 million) in a series C round co-led by swissfirst and Temasek. Other investors included Carnegie Fund; CDIB Bioscience; CITA; MVI Finance; Schroder ISF; Alta...
07:00 , Jun 4, 2001 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Cytos Biotechnology AG Zurich, Switzerland Technology: Immunodrugs displaying highly repetitive and highly ordered arrays of antigens Disease focus: Inflammatory and infectious diseases, allergies, cancer and Alzheimer's disease Clinical status: Preclinical Founded: 1995 by Wolfgang Renner,...
07:00 , Jun 4, 2001 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Cytos Biotechnology AG Zurich, Switzerland Technology: Immunodrugs displaying highly repetitive and highly ordered arrays of antigens Disease focus: Inflammatory and infectious diseases, allergies, cancer and Alzheimer's disease Clinical status: Preclinical Founded: 1995 by Wolfgang Renner,...
07:00 , Jul 25, 2000 |  BC Extra  |  Financial News

Cytos raises CHF50 million

Cytos (Zurich, Switzerland), a protein drug discovery company, raised CHF50 million ($32 million) in a second venture round. Investors included Global Life Science; Innoventure; Novartis (SWX:NOVN; NVS); Alta Partners; Aventic; HealthCap; Lombard Odier; New Medical...